NASDAQ: CASI

Partnering Presentation

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

CASI Pharmaceuticals

CASI Pharmaceuticals Overview

CASI (NASDAQ: CASI) is a U.S. biopharmaceutical company focused on the acquisition, development, and commercialization of high quality, innovative therapeutics addressing cancer and other unmet medical needs, with a **focus on China and the U.S.**

Corporate Headquarters in Maryland, U.S.A. with a wholly owned subsidiary and local R&D Center and commercial operation in Beijing, China. State-of-the-art manufacturing site to be built by CASI joint venture in 2019.

CASI China, Beijing

- Discovery Research
- Regulatory Affairs
- Clinical Development
- Business Development
- Finance
- Commercial
- Manufacturing (Under construction)

Corporate Headquarters

- Corporate Administration
- Clinical Development
- Regulatory Affairs
- Business Development
- Finance / Investor Relations
- Legal

CASI Pharmaceuticals

Business Strategy

Building Shareholder Value by Focusing on Pharmaceutical Growth Segments in China and the U.S.

- **High Value Innovative Medicines**
  - Addressing unmet medical needs in Oncology/Hematology, Hepatitis and Liver Diseases, etc.
- **High Quality Generic Therapeutics**
  - Providing high quality medicinal products to large commercial markets

Bringing Innovative Medicines and High Quality Generics to 1.4 Billion People in Greater China while Addressing the U.S. and Global Markets Efficiently

CASI Pharmaceuticals

Business Strategy

CASI is uniquely positioned to capitalize on recent NMPA reforms to bring innovative products & ANDAs into the China market

- Recent National Medical Products Administration* (NMPA) (China FDA) reforms ensure quality and allow for expedited approval of NDAs and ANDAs for innovative and high quality products
- Accelerate development, registration and commercialization of products for both the China and U.S./Global markets
  - Large population in China for rapid patient recruitment to reach value inflection points quickly and cost-effectively
- High quality, low cost manufacturing by FDA-approved GMP facilities in China can be leveraged on a worldwide basis

***The National Medical Products Administration (NMPA) is the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administration or CFDA)

CASI Pharmaceuticals

Innovative Medicines

*Exclusive China Regional Licenses**

- **EVOMELA® (Melphalan Hydrochloride for Injection): China Marketing Approval Dec 3, 2018 under its new priority review guidelines**
  - ***Indication:*** *use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, and the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate*
- **ZEVALIN®:** NMPA CTA review in progress
  - ***Indication:*** *treatment of non-Hodgkin's Lymphoma*
- **MARQIBO®:** NMPA CTA review in progress
  - ***Indication:*** *treatment of acute lymphoblastic leukemia*
- **CASI responsible for development and commercialization in China, including Taiwan, Hong Kong, and Macau**
  - Import drug registration applications
  - Confirmatory clinical studies
  - Premarketing and commercial launches

* Development & Commercialization Partnership with Spectrum Pharmaceuticals

CASI Pharmaceuticals

Cost Effective, High Quality Generics

Acquired 30 ANDA Products & Pipeline Assets

26 US FDA-Approved ANDAs, 4 Pending FDA Approval ANDAs



Key Products	Indication
Entecavir	cHBV Infection
Tenofovir Disoproxil Fumarate (TDF)	cHBV Infection
Ondansetron	CINV
Repaglinide	Diabetes
Bisoprolol Fumarate	Hypertension
Cilostazol	Vascular Disease

Historical Opportunity for Rapid Entry of FDA-Approved ANDAs in China

CASI Pharmaceuticals

Liver Disease – Addressing a Large Medical Need in China

- **CASI is uniquely positioning itself to provide a portfolio of innovative and high quality products for liver disease to the China Region**
- **Acquired Entecavir for the treatment of chronic hepatitis B virus (cHBV) –** as part of a portfolio of 25 U.S. FDA-approved ANDAs from Sandoz
- **Acquired Tenofovir Disoproxil Fumarate (TDF) for the treatment of chronic hepatitis B virus (cHBV) –** U.S. FDA-approved ANDA from Laurus Labs
- **Proactively partnering to develop and market other products for HBV, HCC, NASH and other liver diseases**

CASI Pharmaceuticals

GMP Manufacturer Facility Under Construction in China

- State-of-the-art GMP manufacturing facility strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China

- Large scale production: yearly output capacity of >4 billion tablets with maximum capacity of 12 billion tablets in long term

CASI Pharmaceuticals

CASI Pharmaceuticals Overview

- **Management:** Experienced team with accomplished track record in North America and China
- **Diversified product portfolio:** Innovative medicines and high quality generic products
- **Successful track record:** Significant experience developing innovative therapeutics and a track record of successful NMPA filings and approvals
- **Well-capitalized:** Strong financial position, backed by successful investment funds; efficient financial management with low burn rate
- **Compelling business model:** Capitalizing on U.S./China synergies & competitive advantages for efficient drug development and commercialization

CASI Board & Management Team

-- Experienced team with accomplished track record in the U.S. and China

BOARD OF DIRECTORS

Wei-Wu He, Ph.D, *Exec Chairman*	IDG-ACCEL China Fund Venture Partner; Managing Director, ETP Global Fund, L.P.; Chairman & CEO, OriGene Technologies, Inc.
Quan Zhou, Ph.D	Founder, Managing Director and General Partner at IDG Capital Partners
James Huang	General Partner, Kleiner Perkins Caufield & Byers China; Manager Partner, Panacea Venture
Rajesh C. Shrotriya, M.D.	Former Chairman & CEO, Spectrum Pharmaceuticals, Inc.
Y. Alexander Wu, Ph.D.	Former CEO and co-founder, Crown Biosciences, Inc.; consultant
Franklin C. Salisbury, Jr.	President, National Foundation for Cancer Research

SENIOR MANAGEMENT

Dr. Ken K. Ren, Ph.D.	Chief Executive Officer and Director
Larry Zhang	President, CASI China
George Chi, CPA, CFA	Chief Financial Officer
Cynthia W. Hu, J.D.	Chief Operating Officer, General Counsel & Secretary
Alexander A. Zukiwski, M.D.	Chief Medical Officer
James E. Goldschmidt, Ph.D.	Senior Vice President, Business Development

CASI Pharmaceuticals

Providing Therapeutic Solutions with a Diversified Product Portfolio

Through Acquisitions, In-licensing and Internally Developed

Innovative, Targeted Oncology Therapeutics and High Quality ANDAs

Greater China Rights

Acquired From SPPI

Evomela (melphalan) for Injection
50 mg per vial

ZEVALIN® (ibritumomab tiuxetan)
INJECTION FOR INTRAVENOUS USE

Marqibo (vinCRIStine sulfate LIPOSOME injection)

US FDA ANDAs

Acquired From Sandoz

25 FDA Approved ANDAs

4 FDA Pending ANDAs

Acquired TDF from Laurus



ENMD-2076, Global Rights

Innovative Drug Candidate Targeted Therapy for Solid Tumors



CASI Pharmaceuticals

Core Capabilities

Fully integrated, China/U.S. operations dedicated to all aspects of development and commercialization

- **Regulatory Affairs Group -** strong working relationships with the CFDA and U.S. FDA
- **Clinical/Medical Team - e**xtensive industry experience and training in oncology/hematology
- **Clinical Operations and Pharmacovigilance Team -** specialized in the management of clinical data to ensure swift and accurate reporting
- **CMC Team -** expertise in all areas of CMC and GMP regulations
- **Marketing and Sales Organization** – oncology/hematology sales team of experienced pharmaceutical professionals – launching EVOMELA® in 2019
- **State-of-the-art cGMP manufacturing plant in Wuxi, China** – breaking ground in 2019

CASI's Value Proposition

A strategic partner for developing and commercializing innovative and high quality therapeutics in China and the U.S.

- Leverage CASI Pharmaceutical's expertise and resources in China to accelerate development and commercialization into the China and U.S./global markets
- Reach value inflection points quickly to support global development programs
  - Rapid patient recruitment, strong relationships with KOLs and major hospitals in China
- Capitalize on the National Medical Products Administration (China FDA's) recent guidance to accept data from overseas clinical trials to accelerate approvals of innovative and high quality drugs
- **Bringing innovative medicines and high quality generics to 1.4 billion people in Greater China while addressing the U.S. and global markets efficiently**


CASI
Pharmaceuticals